Dragon210331 (Talk | contribs) |
Dragon210331 (Talk | contribs) |
||
(10 intermediate revisions by the same user not shown) | |||
Line 1: | Line 1: | ||
{{CKWA-China/header}} | {{CKWA-China/header}} | ||
<html> | <html> | ||
− | + | <style> | |
+ | .tp-leftarrow.tparrows.hermes, .tp-rightarrow.tparrows.hermes{ | ||
+ | display: none; | ||
+ | } | ||
+ | </style> | ||
<!--Main Slider--> | <!--Main Slider--> | ||
<section class="main-slider"> | <section class="main-slider"> | ||
Line 14: | Line 18: | ||
data-param4="" data-param5="" data-param6="" data-param7="" data-param8="" data-param9="" | data-param4="" data-param5="" data-param6="" data-param7="" data-param8="" data-param9="" | ||
data-rotate="0" data-saveperformance="off" data-slotamount="default" | data-rotate="0" data-saveperformance="off" data-slotamount="default" | ||
− | data-thumb=" | + | data-thumb="" data-title="Slide Title" |
data-transition="parallaxvertical"> | data-transition="parallaxvertical"> | ||
Line 28: | Line 32: | ||
data-y="['middle','middle','middle','middle']" | data-y="['middle','middle','middle','middle']" | ||
data-frames='[{"from":"y:[100%];z:0;rX:0deg;rY:0;rZ:0;sX:1;sY:1;skX:0;skY:0;","mask":"x:0px;y:0px;s:inherit;e:inherit;","speed":1500,"to":"o:1;","delay":1000,"ease":"Power3.easeInOut"},{"delay":"wait","speed":1000,"to":"auto:auto;","mask":"x:0;y:0;s:inherit;e:inherit;","ease":"Power3.easeInOut"}]'> | data-frames='[{"from":"y:[100%];z:0;rX:0deg;rY:0;rZ:0;sX:1;sY:1;skX:0;skY:0;","mask":"x:0px;y:0px;s:inherit;e:inherit;","speed":1500,"to":"o:1;","delay":1000,"ease":"Power3.easeInOut"},{"delay":"wait","speed":1000,"to":"auto:auto;","mask":"x:0;y:0;s:inherit;e:inherit;","ease":"Power3.easeInOut"}]'> | ||
− | <h4> | + | <h4>LonEase--a Natural Protease</h4> |
</div> | </div> | ||
Line 38: | Line 42: | ||
data-y="['middle','middle','middle','middle']" | data-y="['middle','middle','middle','middle']" | ||
data-frames='[{"from":"y:[100%];z:0;rX:0deg;rY:0;rZ:0;sX:1;sY:1;skX:0;skY:0;","mask":"x:0px;y:0px;s:inherit;e:inherit;","speed":1500,"to":"o:1;","delay":1000,"ease":"Power3.easeInOut"},{"delay":"wait","speed":1000,"to":"auto:auto;","mask":"x:0;y:0;s:inherit;e:inherit;","ease":"Power3.easeInOut"}]'> | data-frames='[{"from":"y:[100%];z:0;rX:0deg;rY:0;rZ:0;sX:1;sY:1;skX:0;skY:0;","mask":"x:0px;y:0px;s:inherit;e:inherit;","speed":1500,"to":"o:1;","delay":1000,"ease":"Power3.easeInOut"},{"delay":"wait","speed":1000,"to":"auto:auto;","mask":"x:0;y:0;s:inherit;e:inherit;","ease":"Power3.easeInOut"}]'> | ||
− | <h2> | + | <h2>Suppress Cancer Recurrence </h2> |
</div> | </div> | ||
Line 48: | Line 52: | ||
data-y="['middle','middle','middle','middle']" | data-y="['middle','middle','middle','middle']" | ||
data-frames='[{"from":"y:[-100%];z:0;rX:0deg;rY:0;rZ:0;sX:1;sY:1;skX:0;skY:0;","mask":"x:0px;y:0px;s:inherit;e:inherit;","speed":1500,"to":"o:1;","delay":1000,"ease":"Power3.easeInOut"},{"delay":"wait","speed":1000,"to":"auto:auto;","mask":"x:0;y:0;s:inherit;e:inherit;","ease":"Power3.easeInOut"}]'> | data-frames='[{"from":"y:[-100%];z:0;rX:0deg;rY:0;rZ:0;sX:1;sY:1;skX:0;skY:0;","mask":"x:0px;y:0px;s:inherit;e:inherit;","speed":1500,"to":"o:1;","delay":1000,"ease":"Power3.easeInOut"},{"delay":"wait","speed":1000,"to":"auto:auto;","mask":"x:0;y:0;s:inherit;e:inherit;","ease":"Power3.easeInOut"}]'> | ||
− | <div class="text"> | + | <div class="text">2021iGEM ,CWKA-China is coming.</div> |
− | + | ||
</div> | </div> | ||
</li> | </li> | ||
<!-- Slide 2 --> | <!-- Slide 2 --> | ||
− | + | <!-- <li data-description="Slide Description" data-easein="default" data-easeout="default" | |
data-fsmasterspeed="1500" data-fsslotamount="7" data-fstransition="fade" | data-fsmasterspeed="1500" data-fsslotamount="7" data-fstransition="fade" | ||
data-hideafterloop="0" data-hideslideonmobile="off" data-index="rs-1682" | data-hideafterloop="0" data-hideslideonmobile="off" data-index="rs-1682" | ||
Line 97: | Line 100: | ||
installing floorssince 1992 and have installed flooring and Tilling</div> | installing floorssince 1992 and have installed flooring and Tilling</div> | ||
</div> | </div> | ||
− | </li> | + | </li> --> |
− | + | <!-- Slide 3 --> | |
− | + | <!-- <li data-description="Slide Description" data-easein="default" data-easeout="default" | |
data-fsmasterspeed="1500" data-fsslotamount="7" data-fstransition="fade" | data-fsmasterspeed="1500" data-fsslotamount="7" data-fstransition="fade" | ||
data-hideafterloop="0" data-hideslideonmobile="off" data-index="rs-1683" | data-hideafterloop="0" data-hideslideonmobile="off" data-index="rs-1683" | ||
Line 143: | Line 146: | ||
installing floorssince 1992 and have installed flooring and Tilling</div> | installing floorssince 1992 and have installed flooring and Tilling</div> | ||
</div> | </div> | ||
− | </li> | + | </li> --> |
<!-- Slide 4 --> | <!-- Slide 4 --> | ||
− | + | <!-- <li data-description="Slide Description" data-easein="default" data-easeout="default" | |
data-fsmasterspeed="1500" data-fsslotamount="7" data-fstransition="fade" | data-fsmasterspeed="1500" data-fsslotamount="7" data-fstransition="fade" | ||
data-hideafterloop="0" data-hideslideonmobile="off" data-index="rs-1684" | data-hideafterloop="0" data-hideslideonmobile="off" data-index="rs-1684" | ||
Line 188: | Line 191: | ||
<div class="text">2021iGEM ,CWKA-China is coming.</div> | <div class="text">2021iGEM ,CWKA-China is coming.</div> | ||
</div> | </div> | ||
− | </li> | + | </li> --> |
</ul> | </ul> |
Latest revision as of 07:57, 21 October 2021
LonEase
Recurrence of cancer after surgical treatment is a major problem facing mankind nowadays, and cancer recurrence is a great threat for cancer patients. For example, bladder cancer recurs in up to 24%-84% of patients 5 years after surgical resection, in which overexpression of C-MYC protein is associated with approximately 44%-69% of these cases. We have investigated that Lon protein from uropathogenic Escherichia coli (UPEC) can be effective enough to degrade C-MYC protein and thus inhibit the proliferation of cancer cells. We plan to produce highly active Lon protease from E. coli this year and use it to design a drug to improve the surgical prognosis of bladder cancer population with C-myc gene overexpression.